Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

625.65 -15.21 (-2.37%)
Official Closing Price Updated: 7:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Gartner, Eli Lilly, And The Trade Desk Are Among Top 10 Large Cap Losers Last Week (August 4-August 8): Are The Others In Your Portfolio?
Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly. 
Via Benzinga
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Eli Lilly and Company reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines. However, shares of Eli Lilly stock tumbled 14%. Here are ETFs with... 
Via Talk Markets
Topics ETFs
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. 
Via MarketBeat
Topics Government World Trade
Benzinga Bulls And Bears: AMD, Apple, Eli Lilly — And Wall Street Treads Water
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
Trump's Gold Tariffs Shake Markets, Eli Lilly Plunges, Oil Dips On US-Russia Deal, Jobs Miss Fuels Recession Fears — This Week In Economy
The past week saw market turbulence, with President Trump's new gold tariffs, Eli Lilly's dramatic stock drop, a weakening jobs report fueling recession fears, and a divided Federal Reserve debating... 
Via Benzinga
Topics Economy Government World Trade
Why Novo Nordisk Stock Flew Higher on Friday
It looked good next to a company that has been stealing its thunder lately. 
Via The Motley Fool
Why Eli Lilly Stock Sank 18% This Week
The drugmaker is in a 35% drawdown. 
Via The Motley Fool
Topics World Trade
Apple Notches Best Week In Years, Trump Shakes Fed Leadership: This Week In Markets
After a dip last week, Wall Street rebounded as earnings remained strong. Tech stocks surged, but Eli Lilly struggled. Trump imposed tariffs on India and nominated Stephen Miran for Fed seat. 
Via Benzinga
Topics Economy Government World Trade
Wall Street's Resilient Rally: What's Driving the Positive Momentum
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
Expert Outlook: Eli Lilly Through The Eyes Of 4 Analysts
 
Via Benzinga
Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst
Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength. 
Via Benzinga
In today's session, there are S&P500 stocks with remarkable trading volume.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone. 
Via MarketBeat
SoundHound Stock Rallies On Huge Revenue Jump
SoundHound stock rallied Friday after the conversational AI technology company posted a huge gain in revenue. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Does This $856 Million Investment Make Eli Lilly Stock a Buy?
The drugmaker continues to grab headlines for all the right reasons. 
Via The Motley Fool
Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
Eli Lilly has normally been a market-beating stock, but not this year. 
Via The Motley Fool
Topics Economy World Trade
Apple's $704 Billion Decade-Long Buybacks Exceed Market Cap Of All But 13 Companies Worldwide
Apple's $704B in buybacks over 10 years exceeds the market cap of 488 S&P 500 firms. Learn why it still avoids major acquisitions. 
Via Benzinga
Topics Stocks
Stock Market Today: S&P 500, Nasdaq 100 Futures Rise As Trump Appoints New Fed Governor—Beauty Health, RealReal, Twilio In Focus On Q2 Earnings
U.S. stock futures rose on Friday after ending on a mixed note on Thursday. Futures of major benchmark indices were higher. 
Via Benzinga
Topics Economy Government Stocks
Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?
Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lily 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide. 
Via Benzinga
Dow Tumbles Over 200 Points Following Earnings Reports: Fear & Greed Index Remains In 'Neutral' Zone
CNN's Fear & Greed Index declined but remained in Neutral zone on Thursday. Dow fell 200 points, while Apple, Eli Lilly reported earnings. 
Via Benzinga
Topics Stocks
Market Monitor News August 08 BMO - Tariffs, Tablets, and Turbulence: Wall Street Sways Under Trade War Fears and Pharma Fallout
Wall Street ended Thursday on a shaky note as disappointing drug trial results, new trade tariffs, and cautious corporate guidance weighed on sentiment. While Apple (AAPL | +3.2%) basked in the glow of... 
Via Chartmill
Topics World Trade
The Trade Desk, SoundHound AI, Eli Lilly, Block And CrowdStrike: Why These 5 Stocks Are On Investors' Radars Today
The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70 
Via Benzinga
Topics Artificial Intelligence
Eli Lilly Stock Marks Worst Day In 25 Years As Weight-Loss Pill Data Disappoints: Analysts Divided But Retail Bets On Rebound
Via Stocktwits
Eli Lilly Stock Sell-Off ‘Overdone’ As Weight-Loss Pill Remains ‘Commercially Viable’
Eli Lilly's late-stage data for weight-loss pill falls short of expectations. 
Via Talk Markets
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98... 
Via MarketMinute
Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling?
Gilead Sciences boosted its full-year outlook after beating expectations. Gilead stock is hitting a 50-day line ceiling. 
Via Investor's Business Daily
Why Eli Lilly (LLY) Shares Are Getting Obliterated Today
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong... 
Via StockStory
Stay informed with the top movers within the S&P500 index on Thursday.
Let's delve into the developments on the US markets one hour before the close of the markets on Thursday. Below, you'll find the top gainers and losers within the S&P500 index during today's session. 
Via Chartmill
Eli Lilly (NYSE:LLY) Reports Bullish Q2 But Stock Drops 14.4%
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 37.6% year on year to $15.56 billion. The company’s full-year revenue... 
Via StockStory
Elanco (NYSE:ELAN) Delivers Impressive Q2, Stock Jumps 15.4%
Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.8% year on year to $1.24 billion. Guidance for next quarter’s revenue was... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.